They found that low expression of RBsig separated a subset of ER+/HER2+ breast cancer patients with low pCR rates as they were resistant to neoadjuvant chemotherapy, anti-HER2 therapy and CDK4/6 inhibitor combinations 55. This evidence concerns the gene ERBB2 and breast cancer.